Skip to main content
Top
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

Significance of PRO2000/ANCCA expression, a novel proliferation-associated protein in hepatocellular carcinoma

Authors: Jie Yang, Jie Huang, Luqiao Luo, Zhenzhu Chen, Ying Guo, Linlang Guo

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

PRO2000/ANCCA may be an important candidate gene which located within a region of chromosome 8q in hepatocellular carcinoma (HCC). However, its significance remains unclear. The aim of this study was to explore the clinical significance of PRO2000/ANCCA expression in HCC.

Methods

The correlations of PRO2000/ANCCA expression with clinicopathological factors and prognosis of HCC patients were analyzed. Expression of PRO2000/ANCCA, ki-67, cyclinD1, p53 and p21 was detected in HCCs from 107 patients along with corresponding non-tumor tissues by immunohistochemistry.

Results

PRO2000/ANCCA expression was present in 66 of 107 (64.94%) HCC specimens in which 36 of 76 (47.37%) in well differentiated tumors and 30 of 31 (96.77%) in poorly differentiated tumors respectively, while 8 (7.48%) in adjacent non-tumor tissues with scattered positive cells. PRO2000/ANCCA expression was associated with clinicopathological features such as histological differentiation, number of tumor nodules, TNM stage, tumor microsatellite, portal vein tumor thrombus and recurrence, but not with gender, age, tumor size, cirrhosis, HBV infection and serum fetoprotein (AFP) level. There was a close relationship between PRO2000/ANCCA and ki-67 and cyclinD1 in HCC. PRO2000/ANCCA immunopositivity was independent of p53 and p21WAF1/Cip1.

Conclusions

Increased expression of PRO2000/ANCCA is associated with adverse outcome in patients with HCC and is a predictor of poor prognosis for HCC. PRO2000/ANCCA may be involved in the development of HCC and might promote cell proliferation through a p53/ P21WAF1/Cip1-independent pathway.
Appendix
Available only for authorised users
Literature
1.
go back to reference Perry JF, Poustchi H, George J, Farrell GC, McCaughan GW, Strasser SI: Current approaches to the diagnosis and management of hepatocellular carcinoma. Clin Exp Med. 2005, 5 (1): 1-13. 10.1007/s10238-005-0058-3.CrossRefPubMed Perry JF, Poustchi H, George J, Farrell GC, McCaughan GW, Strasser SI: Current approaches to the diagnosis and management of hepatocellular carcinoma. Clin Exp Med. 2005, 5 (1): 1-13. 10.1007/s10238-005-0058-3.CrossRefPubMed
2.
go back to reference Srivatanakul P, Sriplung H, Deerasamee S: Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev. 2004, 5 (2): 118-125.PubMed Srivatanakul P, Sriplung H, Deerasamee S: Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev. 2004, 5 (2): 118-125.PubMed
3.
go back to reference Crawley JJ, Furge KA: Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol. 2002, 3: 12-RESEARCH0075CrossRef Crawley JJ, Furge KA: Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data. Genome Biol. 2002, 3: 12-RESEARCH0075CrossRef
4.
go back to reference Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW: ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A. 2007, 104 (46): 18067-18072. 10.1073/pnas.0705814104.CrossRefPubMedCentralPubMed Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW: ANCCA, an estrogen-regulated AAA + ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci U S A. 2007, 104 (46): 18067-18072. 10.1073/pnas.0705814104.CrossRefPubMedCentralPubMed
5.
go back to reference Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW: Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009, 69 (8): 3339-3346. 10.1158/0008-5472.CAN-08-3440.CrossRefPubMed Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, Chen HW: Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009, 69 (8): 3339-3346. 10.1158/0008-5472.CAN-08-3440.CrossRefPubMed
6.
go back to reference Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S: Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010, 29 (37): 5171-5181. 10.1038/onc.2010.259.CrossRefPubMed Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, Barbry P, Debernardi A, Brambilla C, Brambilla E, Rousseaux S, Khochbin S: Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010, 29 (37): 5171-5181. 10.1038/onc.2010.259.CrossRefPubMed
7.
go back to reference Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K: ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009, 69 (21): 8491-8498. 10.1158/0008-5472.CAN-09-2131.CrossRefPubMed Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, Nucifero P, Pacchiana G, Capra M, Christensen J, Helin K: ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009, 69 (21): 8491-8498. 10.1158/0008-5472.CAN-09-2131.CrossRefPubMed
8.
go back to reference Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW: Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate. 2012, 73: 455-466.CrossRefPubMed Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, Chen HW: Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate. 2012, 73: 455-466.CrossRefPubMed
9.
go back to reference Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Broet S, Vaylet F, Leroy-Ladurie F, Soria JC, Fouret P: A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res. 2012, 18 (20): 5606-5616. 10.1158/1078-0432.CCR-12-0505.CrossRefPubMed Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, Girard P, Camilleri-Broet S, Vaylet F, Leroy-Ladurie F, Soria JC, Fouret P: A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res. 2012, 18 (20): 5606-5616. 10.1158/1078-0432.CCR-12-0505.CrossRefPubMed
10.
go back to reference Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW: Deregulated E2F and the AAA + coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res. 2010, 8: 183-193. 10.1158/1541-7786.MCR-09-0095.CrossRefPubMed Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW: Deregulated E2F and the AAA + coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res. 2010, 8: 183-193. 10.1158/1541-7786.MCR-09-0095.CrossRefPubMed
11.
go back to reference Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW: ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010, 70 (22): 9402-9412. 10.1158/0008-5472.CAN-10-1199.CrossRefPubMedCentralPubMed Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, Cardiff RD, Borowsky AD, Chen HW: ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010, 70 (22): 9402-9412. 10.1158/0008-5472.CAN-10-1199.CrossRefPubMedCentralPubMed
12.
go back to reference Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB: Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013, 8 (2): e54873-10.1371/journal.pone.0054873.CrossRefPubMedCentralPubMed Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, Zack TI, Krohn A, Werner HM, Moody SE, Wik E, Stefansson IM, Holst F, Oyan AM, Tamayo P, Mesirov JP, Kalland KH, Akslen LA, Simon R, Beroukhim R, Salvesen HB: Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013, 8 (2): e54873-10.1371/journal.pone.0054873.CrossRefPubMedCentralPubMed
13.
go back to reference Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H, Ji H: ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma. Ann Surg Oncol. 2013, 20 (Suppl 3): S577-S582.CrossRefPubMed Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H, Ji H: ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma. Ann Surg Oncol. 2013, 20 (Suppl 3): S577-S582.CrossRefPubMed
14.
go back to reference Kaita KD, Pettigrew N, Minuk GY: Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver. 1997, 17 (1): 13-16. 10.1055/s-2007-1007179.CrossRefPubMed Kaita KD, Pettigrew N, Minuk GY: Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver. 1997, 17 (1): 13-16. 10.1055/s-2007-1007179.CrossRefPubMed
15.
go back to reference Gladden AB, Diehl JA: Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem. 2005, 96 (5): 906-913. 10.1002/jcb.20613.CrossRefPubMed Gladden AB, Diehl JA: Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem. 2005, 96 (5): 906-913. 10.1002/jcb.20613.CrossRefPubMed
16.
go back to reference Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W, Janicot M, Vialard JE: p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res. 2005, 3 (11): 627-634. 10.1158/1541-7786.MCR-05-0121.CrossRefPubMed Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N, Andries L, Kass S, Luyten W, Janicot M, Vialard JE: p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res. 2005, 3 (11): 627-634. 10.1158/1541-7786.MCR-05-0121.CrossRefPubMed
17.
go back to reference El-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54 (5): 1169-1174.PubMed El-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54 (5): 1169-1174.PubMed
18.
go back to reference El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75 (4): 817-825. 10.1016/0092-8674(93)90500-P.CrossRefPubMed El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75 (4): 817-825. 10.1016/0092-8674(93)90500-P.CrossRefPubMed
19.
go back to reference Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75 (4): 805-816. 10.1016/0092-8674(93)90499-G.CrossRefPubMed Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75 (4): 805-816. 10.1016/0092-8674(93)90499-G.CrossRefPubMed
20.
go back to reference Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994, 54 (13): 3391-3395.PubMed Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994, 54 (13): 3391-3395.PubMed
21.
go back to reference Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994, 211 (1): 90-98. 10.1006/excr.1994.1063.CrossRefPubMed Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res. 1994, 211 (1): 90-98. 10.1006/excr.1994.1063.CrossRefPubMed
22.
go back to reference Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55 (22): 5187-5190.PubMed Waldman T, Kinzler KW, Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55 (22): 5187-5190.PubMed
23.
go back to reference Lee TK, Man K, Poon RT, Lo CM, Ng IO, Fan ST: Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol Rep. 2004, 12 (1): 25-31.PubMed Lee TK, Man K, Poon RT, Lo CM, Ng IO, Fan ST: Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. Oncol Rep. 2004, 12 (1): 25-31.PubMed
24.
go back to reference Qin LF, Ng IO, Fan ST, Ng M: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer. 1998, 79 (4): 424-428. 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4.CrossRefPubMed Qin LF, Ng IO, Fan ST, Ng M: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer. 1998, 79 (4): 424-428. 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4.CrossRefPubMed
25.
go back to reference Su JJ, Ban KC, Li Y, Qin LL, Wang HY, Yang C, Ou C, Duan XX, Lee YL, Yang RQ: Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews. World J Gastroenterol. 2004, 10 (24): 3559-3563.CrossRefPubMedCentralPubMed Su JJ, Ban KC, Li Y, Qin LL, Wang HY, Yang C, Ou C, Duan XX, Lee YL, Yang RQ: Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews. World J Gastroenterol. 2004, 10 (24): 3559-3563.CrossRefPubMedCentralPubMed
Metadata
Title
Significance of PRO2000/ANCCA expression, a novel proliferation-associated protein in hepatocellular carcinoma
Authors
Jie Yang
Jie Huang
Luqiao Luo
Zhenzhu Chen
Ying Guo
Linlang Guo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-14-33

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine